Cessation of Long Term NAs vs. Keeping on NAs Among CHB Patients (CNAVK)

• Status: Recruiting
• Trial end date: 2024-06-30
• Target enrollment: 0
• Participant gender: All

Summary

To Identify the collected cases who can stop NAs safely with satisfactory clinical outcome including sustain viral remission and HBsAg clearance among chronic hepatitis B(CHB) patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Humanity & Health Medical Group Limited

Criteria

Inclusion Criteria:

1. HBsAg positive, HBeAg negative, antibody to HBeAg-positive;

2. Stable administration of anti-HBV neucleos(t)ides analogue mono therapy for at least more than one and a half year;

3. Demonstration of undetectable HBV DNA on three occasions, each at least 6 months apart, which is consistent with the APASL stopping rule;

4. Patients read, understand the consent form, and signed the study consent.

Exclusion Criteria:

1. Patient with other liver diseases;

2. Patient with concurrent hepatitis viruses or HIV infection;

3. Patients are reluctant to stop their anti-HBV treatment.